A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.

Trial sponsors are typically responsible for providing the experimental drug or treatment at no cost to patients. However, ...

An update from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology has appointed Australian contract research organisation Beyond ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

In the high-stakes arena of cancer drug development, SU212 was engineered as a safer twist on podophyllotoxin—a toxic killer ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

Diabetes drugs may be doing more than managing blood sugar, they could also shape cancer biology in unexpected ways.

Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT modality, including from GSK, Merck and Roche.

Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key ...

Ionetix, a mid-Michigan cancer treatment company, receives workforce development funding to train employees in advanced drug development technology.